SOURCE: Recordati S.p.A.

February 02, 2007 11:00 ET

Recordati to Meet With the Financial Community and Specialized Press in Milan

MILAN, ITALY -- (MARKET WIRE) -- February 2, 2007 -- Recordati Industria Chimica e Farmaceutica S.p.A. will be hosting a meeting with the financial community and specialized press on

Thursday 8 February 2007 at 5 pm

Palazzo Mezzanotte

Piazza degli Affari, 6 - Milan

At the meeting the results for the full year 2006 will be presented and commented upon and the group's development strategy and objectives for 2007 will be discussed.

A simultaneous translation into English of the proceedings will be available via conference call. Dial-in numbers are:

Italy: + 39 02 802 09 11

UK: + 44 208 7929 750

USA: + 1 866 2396 425

France: + 33 170 700 532

Germany: + 49 69 2222 2225

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,000. A European field force of over 1,000 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2005 was EUR 576.1 million, operating income was EUR 111.1 million and net income was EUR 64.5 million.

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements.

All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

VIA M. CIVITALI, 1 - 20148 MILANO, ITALY - TEL. (39) 02 48787.1 - FAX (39) 02 40073747

CORPORATE COMMUNICATIONS - TEL. (39) 02 48787.576 - FAX (39) 02 40074767

This information is provided by CompanynewsGroup

Contact Information

  • For further information:
    Recordati website: www.recordati.com

    Investor Relations
    Marianne Tatschke
    (39)0248787393
    e-mail: Email Contact

    Media Relations
    Claudio Rossetti
    (Echo Comunicazione d'Impresa)
    (39)02 62694736
    e-mail: Email Contact